Recombinant Anti-EpCAM-CD3 Antibody not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Recurrent or Metastatic Solid Tumors
- Main trialPhase 1
- “Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases”In the company’s words, NCT06093698 on ClinicalTrials.gov
Other drugs for Recurrent or Metastatic Solid Tumors
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 30 Jun 2026 | An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026